Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/66395
Título: | Tumor-targeting polycaprolactone nanoparticles with codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer |
Autor(es): | Pan, Q. Tian, J. Zhu, H. Mao, Z. Oliveira, Joaquim M. Reis, R. L. Xiao, L. |
Palavras-chave: | Cancer therapy PCL nanoparticles Tumor LHRH peptide combinational cancer therapy tumor targeting drug-resistant ovarian cancer |
Data: | Mar-2020 |
Editora: | ACS Publications |
Revista: | ACS Biomaterials Science and Engineering |
Citação: | Pan Q., Tian J., Zhu H., Mao Z., Oliveira J. M., Reis R. L., Xiao L. Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer, ACS Biomaterials Science and Engineering, Vol. 6, Issue 4, pp. 2175-2185, doi:10.1021/acsbiomaterials.0c00163, 2020 |
Resumo(s): | Synergetic treatments that combine chemotherapy with photothermal/photodynamic therapy have been developed as promising new strategies for cancer therapy, especially for drug-resistant cancers. To achieve optimized synergetic outcomes for cancer therapy, it is highly desirable to selectively and simultaneously deliver both chemotherapeutics and near-infrared photosensitizers to the cancer tissues and cells, enhancing local accumulation. Here we report the preparation of poly-ε-caprolactone nanoparticles (PCL NPs) using bovine albumin as a stabilizer; the nanoparticles are loaded with IR780 and paclitaxel (PTX) for combinational phototherapy and chemotherapy. Moreover, in order to enable active targeting toward ovarian cancer, a specific peptide recognizing luteinizing hormone-releasing hormone receptors (LHRH) on ovarian cancer cells was covalently grafted onto the surface of the as-prepared NPs. As a result, LHRH peptide modified PCL (PCL-LHRH) NPs demonstrated increased internalization in ovarian tumor cells in vitro and selective targeting in tumor xenografts in vivo. PTX and IR780 can be efficiently encapsulated into PCL-LHRH NPs by an oil-in-water emulsion and solvent evaporation method. The systematic administration of ovarian tumor targeting PCL-LHRH/IR780-PTX can efficiently hinder the growth of drug-resistant xenografts in vivo with the assistance of an 808 nm near-infrared laser. These findings indicate that peptide mediated tumor targeting multifunctional nanomaterials may have remarkable profits in controlled drug delivery and synergistic therapy on drug-resistant cancer. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/66395 |
DOI: | 10.1021/acsbiomaterials.0c00163 |
ISSN: | 2373-9878 |
Versão da editora: | https://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.0c00163 |
Arbitragem científica: | yes |
Acesso: | Acesso restrito UMinho |
Aparece nas coleções: | 3B’s - Artigos em revistas/Papers in scientific journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
20274-20 ACSBSE Li Xiao.pdf Acesso restrito! | 924,76 kB | Adobe PDF | Ver/Abrir |